Myriad Genetics to sell prenatal testing business to Labcorp for $210M

Myriad Genetics Inc. filed a Form 8-K with the SEC on October 20, 2026, disclosing entry into a material definitive agreement to sell its prenatal health testing business — including Prequel, Foresight, SneakPeek and FirstGene tests — to Labcorp for $210 million in cash plus inventory value.

Detected & updated continuously · Source: Nebula